If you entered a web address please check it was correct.
\nYou can also try Search Page to find the study you are looking for.
"}}},"trialDetailsJson":{"title":"Details Page","returnSearch":"Back to search results","description":"Study Description","identifier":"ViiV Study ID","clinicalID":"Clinicaltrials.gov Identifier","EudraCtID":"EudraCT Number","resultsAvailable":"Has Results Available Below","docAvailable":"Has Results Document Available","studyOverview":"Study Overview","overviewSection":{"conditionsDisplay":"Medical Conditions","product":"Product","collaborators":"Collaborators","dates":"Date","studyType":"Type","phase":"Phase","gender":"Gender","age":"Age","acceptVolunteers":"Accepts Healthy Volunteers"},"studyDocuments":"Study Documents","noDocuments":"No documents available","studyDocumentsAdditionalText":"If you wish to request for Full Study Report, please contact - ","studyDocumentsAdditionalEmail":"GSKClinicalSupportHD@gsk.com","isReleased":{"firstPart":"This study has Protocol and Result summary on ClinicalTrial.gov. Click","secondPart":"to learn more.","linkText":"here"},"mapLocations":"Locations","centralContact":"Central Contact","centralPhone":"Central Contact Phone","centralEmail":"Central Contact Email","mapSection":{"site":"GSK Investigational Site","condition":"Condition","id":"Study ID","city":"City","state":"State","zip":"Zip","country":"Country"},"studyDesign":"Study Design","designSection":{"purpose":"Primary Purpose","allocation":"Allocation","study_design":"Study Design","study_classification":"Study Classification","masking":"Masking","masked_subject":"Masked Subject","masked_caregiver":"Masked Caregiver","masked_investigator":"Masked Investigator","masked_assessor":"Masked Assessor","primary_outcomes":"Primary Outcomes","secondary_outcomes":"Secondary Outcomes","arms":"Arms","interventions":"Interventions","keyword":"Keyword","inclusionTitle":"Inclusion Criteria","exclusionTitle":"Exclusion Criteria","criteriaText":"Inclusion/Exclusion Criteria","criteria_button":"Click to view inclusion/exclusion criteria","enrollment":"Enrollment","clinicalPublications":"Clinical Publications"},"popoversText":{"studyId":{"childMarkdownRemark":{"html":"A unique number for a study given by ViiV.
"}},"ctGov":{"childMarkdownRemark":{"html":"This number identifies the study on the US clinicaltrials.gov register. Click this link to go to the entry for this study on Clinicaltrials.gov where you will be able to see protocol and results summaries where available.
"}},"eudraCT":{"childMarkdownRemark":{"html":"This number identifies the study on the EU clinicaltrials.eu register. Click this link to go to the entry for this study on clinicaltrials.eu where you will be able to see protocol and results summaries where available.
"}}}},"site":{"siteMetadata":{"siteUrl":"https://www.viiv-studyregister.com"}},"studyDetails":{"nct_number":"NCT01056874","ctis_id":"","HasResults":"false","IpdAccessCriteria":"","IpdDescription":"","IpdInfoTypeAnalyticCode":"","IpdInfoTypeIcf":"","IpdInfoTypeCsr":"","IpdInfoTypeProtocol":"","IpdInfoTypeSap":"","IpdTimeFrame":"","IpdUrl":"","IsFlexibleTrial":false,"IsReleasedToCtGov":"true","MaskingInfo":{"masked_assessor":"false","masked_caregiver":"false","masked_investigator":"false","masked_subject":"false","masking_description":"","no_masking":""},"PatientLevelData":"false","SharingIpd":"","acronym":"","allocation":"Randomized","arm_groups":[{"arm_group_label":"Digoxin","arm_group_description":"","arm_type":"Active Comparator"},{"arm_group_label":"Digoxin + Maraviroc","arm_group_description":"","arm_type":"Experimental"}],"assignment":"Crossover Assignment","brief_summary":"This is an open labelled study to estimate the effect of maraviroc on the pharmacokinetics of digoxin, a probe for p-glycoprotein.","brief_summary_OneLinkTx":"","brief_title_OneLinkTx":"","brief_title":"Effect Of Maraviroc On The Pharmacokinetics Of Digoxin","conditions":[{"DisplayValue":"Other","DisplayValue_OneLinkTx":"","InternalValue":"CON_OTHER","LookupValue":"Healthy","LookupValue_OneLinkTx":""},{"DisplayValue":"Human Immunodeficiency Virus (HIV)","DisplayValue_OneLinkTx":"","InternalValue":"CON_HIV","LookupValue":"HIV infections","LookupValue_OneLinkTx":""}],"created_date":"09/15/2018 18:05:24","criteria":"Inclusion Criteria: - Healthy male and/or female subjects between the ages of 21 and 55 years, inclusive. - Body Mass Index (BMI) of 17.5 to 25.5 kg/m2. - Total body weight >50 kg (110 lbs). Exclusion Criteria: - Treatment with an investigational drug within 30 days or 5 half-lives (whichever is longer) preceding the first dose of study medication. - Subjects with an estimated creatinine clearance (CLcr) <80 ml/min. - Pregnant or nursing females. - Females of childbearing potential who are unwilling or unable to use an acceptable method of contraception as outlined in this protocol from at least 14 days prior to the first dose of study medication until completion of study.","detailed_description":"","display_gender":"Both","display_gender_internal":"GENDER_ALL","display_phase":"Phase 1","display_phase_internal":"PHASE_1","display_status":"Completed","display_status_internal":"RECSTATUS_I_COMPLETED","endpoint":"","enrollment":"12","exclusion":"","gender":"Both","gender_based":"","gender_description":"","healthy_volunteers":"Yes","id":"01c696d5-ad48-5bed-87a5-e26f7daa765e","internal":{"content":null,"contentDigest":"b7d48456d489a35d15fc8352bfd041ce","description":null,"fieldOwners":null,"mediaType":null,"ignoreType":null,"owner":"default-site-plugin","type":"studyDetails"},"inclusion":"Inclusion Criteria: - Healthy male and/or female subjects between the ages of 21 and 55 years, inclusive. - Body Mass Index (BMI) of 17.5 to 25.5 kg/m2. - Total body weight >50 kg (110 lbs). Exclusion Criteria: - Treatment with an investigational drug within 30 days or 5 half-lives (whichever is longer) preceding the first dose of study medication. - Subjects with an estimated creatinine clearance (CLcr) <80 ml/min. - Pregnant or nursing females. - Females of childbearing potential who are unwilling or unable to use an acceptable method of contraception as outlined in this protocol from at least 14 days prior to the first dose of study medication until completion of study.","interventions":[{"arm_group_label":"Digoxin","intervention_description":"Oral Digoxin 0.25 mg single dose","intervention_name":"Digoxin","intervention_type":"Drug"},{"arm_group_label":"Digoxin + Maraviroc","intervention_description":"Oral Digoxin 0.25 mg single dose on Day 5","intervention_name":"Digoxin","intervention_type":"Drug"},{"arm_group_label":"Digoxin + Maraviroc","intervention_description":"Oral Maraviroc 300 mg twice daily for 6 days","intervention_name":"Maraviroc","intervention_type":"Drug"}],"interventional_subtype":"Treatment","is_fda_regulated":true,"is_high_value":false,"is_ind_study":false,"keywords":["Maraviroc","Digoxin","P-glycoprotein","Pharmacokinetics","Drug Interaction","HIV"],"last_follow_up_date":"04/01/2010 00:00:00","links":[{"description":"To obtain contact information for a study center near you, click here.","url":"https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A4001097&StudyName=Effect%20Of%20Maraviroc%20On%20The%20Pharmacokinetics%20Of%20Digoxin"},{"description":"Link to ClinicalStudyResults.org","url":"http://www.clinicalstudyresults.org/drugdetails/?study_name=A4001097&sort=c.company_name&page=1&drug_id=11273"}],"locations":[{"City":"Singapore","Latitude":"1.301171","CountryDisplay":"Singapore","Longitude":"103.857198","Name":"Pfizer Investigational Site","StateDisplay":null,"PostalCode":"188770","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"}],"masking":"Open Label","maximum_age_raw":"55 Years","maximum_age":"55","minimum_age":"21","minimum_age_raw":"21 Years","modified_date":"10/01/2018 22:56:35","number_of_arms":"2","observational_design":{"biospecimen_description":"","biospecimen_retention":"","number_of_groups":"","observational_study_design":"","patient_registry":"","target_duration_quantity":"","target_duration_units":"","timing":""},"official_title":"Open-Label, Fixed Sequence, Crossover Study To Estimate The Effect Of Multiple Dose Maraviroc On Single Dose Digoxin Pharmacokinetics In Healthy Subjects","org_study_id":"A4001097","overall_contact":{"email":null,"last_name":"Pfizer CT.gov Call Center","phone":"1-800-718-1021"},"overall_status":"Completed - Interventional","oversight_info":{"exported_from_us":"","fda_regulated_device":"","fda_regulated_drug":"","ped_postmarket_surv":"","has_dmc":false,"post_prior_to_approval":"","regulatory_authorities":[""]},"phase":"Phase 1","primary_compl_date":"04/01/2010 00:00:00","primary_outcomes":[{"outcome_description":"","outcome_measure":"To estimate the effect of multiple dose maraviroc on the pharmacokinetics of digoxin.","outcome_time_frame":"21 days","outcome_safety_issue":null}],"product_name":"","product_name_OneLinkTx":"","secondary_ids":[],"secondary_outcomes":[{"outcome_description":"","outcome_measure":"To investigate the safety and tolerability of maraviroc and digoxin when co-administered.","outcome_time_frame":"21 days","outcome_safety_issue":null}],"sponsors":{"investigator_affiliation":"","investigator_username":"","lead_sponsor":"ViiV Healthcare","collaborators":["Pfizer"]},"start_date":"03/01/2010 00:00:00","study_type":"Interventional","therapeutic_area":"","citations":[],"is_section_801":true}},"pageContext":{"studyId":"A4001097"}},"staticQueryHashes":["162689979","3332233851","3729204765","3769354840","399703114"]}